LeadIQ logo
Learn more at LeadIQ.com

Insights

Recent Acquisition APEIRON Biologics was acquired by Ligand Pharmaceuticals for $100M, presenting potential collaboration opportunities with the new parent company.

Expanding Clinical Trials The launch of Phase Ib trial of APN401 for solid tumors indicates a focus on expanding the product pipeline, creating possibilities for partnerships and licensing agreements.

Strategic Collaborations Partnerships with companies like Domainex and Sanofi for therapy development reflect a commitment to innovation and potential avenues for joint ventures to drive sales.

Successful Financing Rounds After closing an oversubscribed financing round of EUR 17.5 million, APEIRON Biologics is well-funded for further product development, signaling opportunities for investment and product commercialization.

Strong Patent Portfolio APEIRON Biologics boasts a strong patent portfolio that can be leveraged for licensing deals and strategic alliances, potentially opening up revenue streams through intellectual property agreements.

Similar companies to APEIRON Biologics AG

APEIRON Biologics AG Tech Stack

APEIRON Biologics AG uses 8 technology products and services including W3 Total Cache, jQuery Migrate, Lightbox, and more. Explore APEIRON Biologics AG's tech stack below.

  • W3 Total Cache
    Caching
  • jQuery Migrate
    Javascript Libraries
  • Lightbox
    Javascript Libraries
  • RSS
    Miscellaneous
  • Debian
    Operating Systems
  • Bootstrap
    UI Frameworks
  • Animate.css
    UI Frameworks
  • Apache HTTP Server
    Web Servers

Media & News

APEIRON Biologics AG's Email Address Formats

APEIRON Biologics AG uses at least 1 format(s):
APEIRON Biologics AG Email FormatsExamplePercentage
First.Last@apeiron-biologics.comJohn.Doe@apeiron-biologics.com
50%
First.Last@apeiron-biologics.comJohn.Doe@apeiron-biologics.com
50%

Frequently Asked Questions

Where is APEIRON Biologics AG's headquarters located?

Minus sign iconPlus sign icon
APEIRON Biologics AG's main headquarters is located at Campus-Vienna-Biocenter 5 Wien, Wien 1030 AT. The company has employees across 2 continents, including EuropeNorth America.

What is APEIRON Biologics AG's official website and social media links?

Minus sign iconPlus sign icon
APEIRON Biologics AG's official website is apeiron-biologics.com and has social profiles on LinkedIn.

What is APEIRON Biologics AG's SIC code NAICS code?

Minus sign iconPlus sign icon
APEIRON Biologics AG's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does APEIRON Biologics AG have currently?

Minus sign iconPlus sign icon
As of April 2024, APEIRON Biologics AG has approximately 12 employees across 2 continents, including EuropeNorth America. Key team members include Chairman Of The Supervisory Board: M. R.Project Head Bei Apeiron Biologics: R. S.Lab Techn: S. S.. Explore APEIRON Biologics AG's employee directory with LeadIQ.

What industry does APEIRON Biologics AG belong to?

Minus sign iconPlus sign icon
APEIRON Biologics AG operates in the Biotechnology Research industry.

What technology does APEIRON Biologics AG use?

Minus sign iconPlus sign icon
APEIRON Biologics AG's tech stack includes W3 Total CachejQuery MigrateLightboxRSSDebianBootstrapAnimate.cssApache HTTP Server.

What is APEIRON Biologics AG's email format?

Minus sign iconPlus sign icon
APEIRON Biologics AG's email format typically follows the pattern of . Find more APEIRON Biologics AG email formats with LeadIQ.

When was APEIRON Biologics AG founded?

Minus sign iconPlus sign icon
APEIRON Biologics AG was founded in 2003.
APEIRON Biologics AG

APEIRON Biologics AG

Biotechnology ResearchWien, Austria11-50 Employees

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.  

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Section iconCompany Overview

Headquarters
Campus-Vienna-Biocenter 5 Wien, Wien 1030 AT
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2003
Employees
11-50

Section iconFunding & Financials

Section iconFunding & Financials

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.